Seat­tle's AGC plots $194M in­vest­ment to dou­ble pro­duc­tion at Copen­hagen site in busy year for bi­o­log­ics

Bi­o­log­ics man­u­fac­tur­ing is an ex­pen­sive and com­pli­cat­ed process — but that hasn’t stopped some of the bio­phar­ma in­dus­try’s biggest play­ers from mak­ing big splash­es in re­cent …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER